Analyst firms · J.P. Morgan · CCCC

J.P. Morgan CCCC price target and rating history

C4 Therapeutics Inc. (CCCC) · Health Care

J.P. Morgan rates C4 Therapeutics Inc. (CCCC) Neutral with a $6 price target, as of its latest action on Jan 29, 2024. It has published 4 rating actions on CCCC since March 2022, including 1 upgrade and 2 downgrades.

Current rating
Neutral
Price target
$6
Median target, all firms
Too few
Actions on CCCC
4

J.P. Morgan price target on CCCC

$22$13$52023202420252026
J.P. Morgan price target on CCCC, each point a stated target, March 2022 to January 2024. Targets before November 2022 (divided by 2) are adjusted for a stock split, going by the prior target J.P. Morgan restated.

Every J.P. Morgan rating on CCCC

How other firms rate CCCC

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Lake StreetBuy$11Oct 28, 2026
TD CowenBuyDec 2, 2025

Questions about J.P. Morgan and CCCC

What is J.P. Morgan's price target for CCCC?
J.P. Morgan's latest stated price target for C4 Therapeutics Inc. (CCCC) is $6, from its action on Jan 29, 2024.
What is J.P. Morgan's rating on CCCC?
J.P. Morgan rates CCCC Neutral, a neutral rating, as of Jan 29, 2024.
When did J.P. Morgan last change its view on CCCC?
On Jan 29, 2024, J.P. Morgan upgrades to Neutral from Underweight, price target $6.

All J.P. Morgan ratingsCCCC news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.